Biosimilars – Forecast – Forecast Methodology And General Market Assumptions
In 2021, sales of branded biologics for oncology, immunology, endocrinology, nephrology, respiratory, and ophthalmology indications exceeded $130 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Sales of biosimilars in these therapy areas and countries totaled approximately $15 billion. Throughout our 2021-2031 forecast period, increasing numbers of branded biologics are set to lose patent protection, and biosimilars are expected to enter the market and erode both patient share and drug prices. We present our forecasts for key reference brands and their biosimilars by therapeutic area, molecule, and country / region.
Biosimilars - Forecast - Forecast Methodology And General Market Assumptions
Brands included in market forecast
General market assumptions
Clinical trials
Approval times and market launch delays
Key regulatory review and launch delay assumptions
United States
EU5
Japan
Indication extrapolation
Pharmacy-level substitution
Biosimilar pricing
Reference-brand pricing
Biosimilar adoption rates
Key assumptions
Biosimilar adoption rates
United States
EU5
Japan
Yashu Malhotra
Yashu Malhotra, M.Pharm., is an analyst on the Biosimilars and Oncology teams at Clarivate. Previously, she was a senior analyst in the life sciences department at Course5 Intelligence. She also worked in competitive intelligence at WNS Global Services. Ms. Malhotra earned her master’s degree in pharmacy (quality assurance) from India’s Delhi Institute of Pharmaceutical Sciences and Research.
